Comparison
Ashwagandha vs Ipamorelin
Side-by-side of Ashwagandha and Ipamorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Ashwagandha
Ashwagandha supplement guide: KSM-66 and Sensoril extracts at 300-600 mg/day cut morning cortisol and stress in RCTs. Dose, side effects, testosterone data.
Ipamorelin
Ipamorelin peptide benefits: selective ghrelin-receptor GHRP, 200 to 300 mcg dosage, GH pulse without cortisol or prolactin rise, CJC-1295 stack vs sermorelin.
Effects at a glance
Ashwagandha
- •Reduces morning serum cortisol by ~20 to 30% at 300 to 600 mg/day standardized extract over 8 weeks
- •Lowers subjective stress on DASS-21 and PSS scales versus placebo in chronically stressed adults
- •Modest grip-strength and 1-RM gains of ~5 to 8% in trained men when paired with resistance training
- •Improves self-reported sleep quality and onset latency in adults with insomnia symptoms
- •Small testosterone increases (~10 to 15%) reported in stressed or subfertile men, less clear in healthy populations
- •May raise free T3 and T4; can interact with levothyroxine and unmask subclinical hyperthyroidism
Ipamorelin
- •Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
- •Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
- •~2 hour plasma half-life, longest of the synthetic GHRPs
- •Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
- •Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
- •Banned by WADA under S2; never reached registration despite phase 2b development
Side-by-side
| Attribute | Ashwagandha | Ipamorelin |
|---|---|---|
| Category | natural | peptide |
| Also known as | Withania somnifera, KSM-66, Sensoril | NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Half-life (hr) ↗ | 10 | 2 |
| Typical dose (mg) ↗ | 600 | 0.2 |
| Dosing frequency | daily | 2-3x daily |
| Routes | oral | subcutaneous, intravenous |
| Onset (hr) | 2 | 0.25 |
| Peak (hr) | - | 1 |
| Molecular weight | - | 711.86 |
| Molecular formula | - | C38H49N9O5 |
| Mechanism | GABAergic modulation and HPA-axis attenuation; withanolides reduce cortisol secretion and inhibit NF-kB signaling. | Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs. |
| Legal status | Dietary supplement in most jurisdictions; regulated in Denmark | Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement | Not scheduled (research chemical) |
| Pregnancy | Not recommended | Insufficient data; not recommended |
| CAS | - | 170851-70-4 |
| PubChem CID | - | 11338566 |
| Wikidata | Q310109 | Q1666741 |
Safety profile
Ashwagandha
Common side effects
- mild GI upset
- drowsiness
- headache
Contraindications
- pregnancy
- autoimmune disease (theoretical immune stimulation)
- hyperthyroidism
- concurrent sedative use
Interactions
- benzodiazepines: additive CNS depression(moderate)
- thyroid hormone (levothyroxine): may raise T3/T4, altering dose requirements(moderate)
- immunosuppressants: theoretical antagonism via immune stimulation(moderate)
Ipamorelin
Common side effects
- injection-site irritation
- vivid dreams
- transient mild head pressure
- occasional headache
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
Interactions
- CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
- sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
Which Should You Take?
Ashwagandha comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Ipamorelin is the right call when one of the conditionals below applies.
- → If your priority is stress and HPA-axis regulation, pick Ashwagandha.
- → If your priority is focus or working memory, pick Ashwagandha.
- → If your priority is growth-hormone axis, pick Ipamorelin.
- → If your priority is post-training recovery, pick Ipamorelin.
Edge case: If you want to avoid research-only / gray-market sourcing, Ashwagandha is the more accessible choice.
Default choice: Ashwagandha. Lower friction to source, and broader goal coverage. Reach for Ipamorelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Ashwagandha and Ipamorelin?
Ashwagandha and Ipamorelin differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Ashwagandha or Ipamorelin?
Ashwagandha half-life is 10 hours; Ipamorelin half-life is 2 hours.
Can you stack Ashwagandha with Ipamorelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper